表纸
市场调查报告书
商品编码
515309

男性不孕症的全球市场:市场规模,占有率,趋势分析 - 检验类型(DNA片断化,氧化压力检测,显微镜检验),治疗方法,各地区

Male Infertility Market Size, Share & Trends Analysis Report By Test (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination), By Treatment, By Region, And Segment Forecasts, 2020 - 2027

出版日期: | 出版商: Grand View Research, Inc. | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
  • 全貌
  • 简介
  • 目录
简介

全球男性不孕症市场在2020年~2027年间,预测将以4.7%的年复合成长率推移,市场规模到2027年达到50亿3,000万美元的规模。诊断检验的技术的进步,及男性不孕症的增加,肥胖人口的增加,以及与生活方式有关的致病性疾病有望推动该市场的增长。依各检验类型来看,DNA片断化将成为2019年最大市场区隔,并将在预测期间维持优势。

本报告提供全球男性不孕症市场调查,提供市场概要,各检验类型·治疗方法·各地区的市场规模的变化与预测,市场成长要素及阻碍因素分析,市场机会,竞争情形,主要企业的简介等全面性资讯。

目录

第1章 调查手法和范围

  • 市场区隔和范围
  • 调查手法
  • 资讯采购
  • 资讯或资料分析
  • 市场形成与检验
  • 模式详细内容
  • 二级资讯来源的清单
  • 调查目的

第2章 摘要整理

  • 市场预测
  • 市场区隔预测
  • 竞争考察
  • 市场展望

第3章 市场变数·趋势·范围

  • 市场系统预测
  • 市场区隔
  • 渗透与成长预测制图
  • 商务环境分析工具
  • 临床试验分析

第4章 男性不孕症市场分析:各检验类型

  • 市场占有率:各检验类型(实际成果值·预测值)
  • 市场区隔仪表板
  • 市场规模:各检验类型(实际成果值·预测值)
    • DNA片断化
    • 氧化压力检测
    • 显微镜检验
    • 精子凝集实验
    • 电脑辅助精子分析
    • 卵子精子渗透试验
    • 其他

第5章 男性不孕症市场分析:各治疗法

  • 市场占有率:各治疗法(实际成果值·预测值)
  • 市场区隔仪表板
  • 市场规模:各治疗法(实际成果值·预测值)
    • 辅助生殖技术医疗(ART)& 精索静脉曲张手术
    • 投药

第6章 男性不孕症市场分析:各地区

  • 市场占有率:各地区(实际成果值·预测值)
  • 市场区隔仪表板
  • 地区市场概述
  • SWOT分析:各地区
  • 市场趋势与市场规模(实际成果值·预测值)
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲

第7章 竞争分析

  • 策略性组成架构/企业区分
  • 业者情势
  • 企业的市场地位分析(地理存在感,产品系列,策略性配合措施)
  • 企业简介
    • EMD Serono, Inc.
    • Endo International plc
    • Sanofi
    • Bayer Group
    • SCSA Diagnostics
    • Halotech DNA SL
    • Intas Pharmaceuticals Ltd.
    • Aytu BioScience, Inc.
    • Cadila Pharmaceuticals
    • Vitrolife

第8章 推荐事项

目录
Product Code: GVR-1-68038-833-6

The global male infertility market size is expected to reach USD 5.03 billion by 2027, expanding at a CAGR of 4.7% over the forecast period, according to a new report by Grand View Research, Inc. Advancements in diagnostic tests and increasing infertility in males are some of the major factors driving the market for male infertility. In addition, lifestyle-associated diseases causing infertility, rising obesity, and growing aging population are likely to boost the market growth during the forecast period. In U.S., one-third of infertility cases are due to female factors, one third due to male factors, and the remaining one third is unknown.

DNA fragmentation technique emerged the largest test segment in the market in 2019 and is expected to maintain its lead during the forecast period. Increasing adoption in developed countries and high cost due to higher sensitivity and reliable analysis of sperm DNA integrity are the key factors driving the segment.

On the basis of treatment, the Assisted Reproductive Technology (ART) and Varicocele Surgery segment dominated the market for male infertility in 2019 due to its high success rate. Intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF) are the most commonly used ARTs. Medications include hormonal therapy and corticosteroids, however they are effective in very few cases.

Partnerships and agreements among key manufacturers are expected to boost the market growth in the coming years. For instance, in July 2019, Vitrolife entered into a collaboration with Prime Tech for the development and exclusive marketing of the Piezo technique, for improved Intracytoplasmic Sperm Injection (ICSI) procedure in human IVF globally except Malaysia, Thailand, and Japan. Additionally, Vitrolife will initiate the regulatory approval procedures in various markets for the future commercialization of the technology.

Further key findings from the study suggest:

Based on test, DNA fragmentation technique dominated the market in 2019 and is estimated to witness significant growth over the forecast period

Oxidative stress analysis test is gaining popularity due to the accurate determination of reactive oxygen species. In March 2018, Aytu BioScience, Inc. received registration from COFEPRIS in Mexico for MiOXSYS System, which is used for diagnosing male infertility

Europe dominated the male infertility market in 2019 and is expected to maintain its lead during the forecast period due to high adoption of costlier treatment, strong diagnosis rate, and increased awareness

Asia Pacific is projected to witness substantial growth over the forecast period owing to increasing investment by several clinics and pharmaceutical companies and growing healthcare expenditure

Some key players of the market are Bayer Healthcare, Inc.; EMD Sereno; Aytu BioScience, Inc.; Halotech DNA SL; Intas Pharmaceuticals Ltd.; Cadila Healthcare Ltd.; Andrology Solutions; and SCSA diagnostics, Inc.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Test
    • 1.1.2 Treatment
    • 1.1.3 Regional Scope
    • 1.1.4 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity flow analysis (Model 1)
    • 1.6.2 Volume price analysis (model 2)
  • 1.7 List of Secondary Sources
  • 1.8 Objectives
    • 1.8.1 Objective - 1
    • 1.8.2 Objective - 2

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
    • 2.2.1 Test
    • 2.2.2 Treatment
    • 2.2.3 Region
  • 2.3 Competitive Insights
  • 2.4 Male Infertility Market Outlook, 2019

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
  • 3.2 Market Segmentation
  • 3.3 Penetration & Growth Prospect Mapping
    • 3.3.1 Penetration Analysis
    • 3.3.2 Market driver analysis
      • 3.3.2.1 High Adoption of Assisted Reproductive Technology (ART)
      • 3.3.2.2 Increasing incidence of infertility
      • 3.3.2.3 Acquisitions, mergers, and partnerships in the market
      • 3.3.2.4 Technological advancements
    • 3.3.3 Market restraint analysis
      • 3.3.3.1 High cost of treatment
  • 3.4 Male Infertility Market: Business Environment Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 PESTEL Analysis
  • 3.5 Clinical Trial Analysis

Chapter 4 Male Infertility Market: Test Analysis

  • 4.1 Male Infertility Test Market Share Analysis, 2019 & 2027
  • 4.2 Male Infertility Test Market: Segment Dashboard:
  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Test Segment
    • 4.3.1 DNA Fragmentation Technique
      • 4.3.1.1 DNA fragmentation technique market, 2015 - 2027 (USD Million)
    • 4.3.2 Oxidative Stress Analysis
      • 4.3.2.1 Oxidative stress analysis market, 2015 - 2027 (USD Million)
    • 4.3.3 Microscopic Examination
      • 4.3.3.1 Microscopic Examination market, 2015 - 2027 (USD Million)
    • 4.3.4 Sperm Agglutination
      • 4.3.4.1 Sperm agglutination market, 2015 - 2027 (USD Million)
    • 4.3.5 Computer Assisted Semen Analysis
      • 4.3.5.1 Computer assisted semen analysis market, 2015 - 2027 (USD Million)
    • 4.3.6 Sperm Penetration Assay
      • 4.3.6.1 Sperm penetration assay market, 2015 - 2027 (USD Million)
    • 4.3.7 Others
      • 4.3.7.1 Others market, 2015 - 2027 (USD Million)

Chapter 5 Male Infertility Market: Treatment Analysis

  • 5.1 Male Infertility Treatment Market Share Analysis, 2019 & 2027
  • 5.2 Male Infertility Treatment Market: Segment Dashboard:
  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2027 for the Treatment Segment
    • 5.3.1 ART & Varicocele Surgery
      • 5.3.1.1 ART & varicocele surgery market, 2015 - 2027 (USD Million)
    • 5.3.2 Medication
      • 5.3.2.1 Medication market, 2015 - 2027 (USD Million)

Chapter 6 Male Infertility Market: Regional Analysis

  • 6.1 Male Infertility Regional Market Share Analysis, 2019 & 2027
  • 6.2 Male Infertility Regional Market: Segment Dashboard
  • 6.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
  • 6.4 SWOT Analysis, by Region
    • 6.4.1 North America
    • 6.4.2 Europe
    • 6.4.3 Asia Pacific
    • 6.4.4 Latin America
    • 6.4.5 MEA
  • 6.5 Market Size, & Forecasts, and Trend Analysis, 2015 to 2027
    • 6.5.1 North America
      • 6.5.1.1 North America male infertility market, 2015 - 2027 (USD Million)
      • 6.5.1.1.1 U.S.
      • 6.5.1.1.1.1 Regulatory & reimbursement scenario
      • 6.5.1.1.1.2 U.S. male infertility market, 2015 - 2027 (USD Million)
      • 6.5.1.1.2 Canada
      • 6.5.1.1.2.1 Regulatory & reimbursement scenario
      • 6.5.1.1.2.2 Canada male infertility market, 2015 - 2027 (USD Million)
    • 6.5.2 Europe
      • 6.5.2.1 Europe male infertility market, 2015 - 2027 (USD Million)
      • 6.5.2.1.1 U.K.
      • 6.5.2.1.1.1 Regulatory & reimbursement scenario
      • 6.5.2.1.1.2 U.K. male infertility market, 2015 - 2027 (USD Million)
      • 6.5.2.1.2 Germany
      • 6.5.2.1.2.1 Regulatory & reimbursement scenario
      • 6.5.2.1.2.2 Germany male infertility market, 2015 - 2027 (USD Million)
    • 6.5.3 Asia Pacific
      • 6.5.3.1 Asia Pacific male infertility market, 2015 - 2027 (USD Million)
      • 6.5.3.1.1 Japan
      • 6.5.3.1.1.1 Regulatory & reimbursement scenario
      • 6.5.3.1.1.2 Japan male infertility market, 2015 - 2027 (USD Million)
      • 6.5.3.1.2 China
      • 6.5.3.1.2.1 Regulatory & reimbursement scenario
      • 6.5.3.1.2.2 China male infertility market, 2015 - 2027 (USD Million)
    • 6.5.4 Latin America
      • 6.5.4.1 Latin America male infertility market, 2015 - 2027 (USD Million)
      • 6.5.4.1.1 Brazil
      • 6.5.4.1.1.1 Regulatory & reimbursement scenario
      • 6.5.4.1.1.2 Brazil male infertility market, 2015 - 2027 (USD Million)
      • 6.5.4.1.2 Mexico
      • 6.5.4.1.2.1 Regulatory & reimbursement scenario
      • 6.5.4.1.2.2 Mexico male infertility market, 2015 - 2027 (USD Million)
    • 6.5.5 Middle East and Africa (MEA)
      • 6.5.5.1 MEA male infertility market, 2015 - 2027 (USD Million)
      • 6.5.5.1.1 South Africa
      • 6.5.5.1.1.1 Regulatory & reimbursement scenario
      • 6.5.5.1.1.2 South Africa male infertility market, 2015 - 2027 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Strategic Framework/ Competition Categorization (Key innovators, Market leaders, emerging players
  • 7.2 Vendor Landscape
    • 7.2.1 Strategy Mapping
    • 7.2.2 Launch of New Products
    • 7.2.3 Merger and Acquisition
    • 7.2.4 Product Approvals
  • 7.3 Company Market Position Analysis (Geographic Presence, Product Portfolio, Strategic Initiatives)
  • 7.4 Company Profiles
    • 7.4.1 EMD Serono, Inc.
      • 7.4.1.1 Company overview
      • 7.4.1.2 Financial performance
      • 7.4.1.3 Product benchmarking
      • 7.4.1.4 Strategic initiatives
    • 7.4.2 Endo International plc
      • 7.4.2.1 Company overview
      • 7.4.2.2 Financial performance
      • 7.4.2.3 Product benchmarking
      • 7.4.2.4 Strategic initiatives
      • 7.4.2.5 SWOT analysis
    • 7.4.3 Sanofi
      • 7.4.3.1 Company overview
      • 7.4.3.2 Financial performance
      • 7.4.3.3 Product benchmarking
      • 7.4.3.4 Strategic initiatives
      • 7.4.3.5 SWOT Analysis
    • 7.4.4 Bayer Group
      • 7.4.4.1 Company overview
      • 7.4.4.2 Financial performance
      • 7.4.4.3 Product benchmarking
      • 7.4.4.4 Strategic initiatives
      • 7.4.4.5 SWOT analysis
    • 7.4.5 SCSA Diagnostics
      • 7.4.5.1 Company overview
      • 7.4.5.2 Product benchmarking
    • 7.4.6 Andrology Solutions
      • 7.4.6.1 Company overview
      • 7.4.6.2 Product benchmarking
    • 7.4.7 Halotech DNA SL
      • 7.4.7.1 Company overview
      • 7.4.7.2 Product benchmarking
      • 7.4.7.3 Strategic initiatives
    • 7.4.8 Intas Pharmaceuticals Ltd.
      • 7.4.8.1 Company overview
      • 7.4.8.2 Financial performance
      • 7.4.8.3 Product benchmarking
      • 7.4.8.4 Strategic initiatives
      • 7.4.8.5 SWOT analysis
    • 7.4.9 Aytu BioScience, Inc.
      • 7.4.9.1 Company overview
      • 7.4.9.2 Financial performance
      • 7.4.9.3 Product Benchmarking
      • 7.4.9.4 Strategic initiatives
      • 7.4.9.5 SWOT Analysis
    • 7.4.10 Cadila Pharmaceuticals
      • 7.4.10.1 Company overview
      • 7.4.10.2 Product benchmarking
      • 7.4.10.3 Strategic initiatives
    • 7.4.11 Vitrolife
      • 7.4.11.1 Company overview
      • 7.4.11.2 Financial performance
      • 7.4.11.3 Product benchmarking
      • 7.4.11.4 Strategic initiatives
      • 7.4.11.5 SWOT Analysis

Chapter 8 Recommendations

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 North America Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 3 North America Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 4 North America Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 5 U.S. Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 6 U.S. Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 7 Canada Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 8 Canada Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 9 Europe Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 10 Europe Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 11 Europe Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 12 U.K. Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 13 U.K. Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 14 Germany Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 15 Germany Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 16 Asia Pacific Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 17 Asia Pacific Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 18 Asia Pacific Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 19 Japan Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 20 Japan Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 21 China Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 22 China Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 23 Latin America Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 24 Latin America Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 25 Latin America Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 26 Brazil Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 27 Brazil Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 28 Mexico Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 29 Mexico Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 30 MEA Male Infertility market, by country, 2015 - 2027 (USD Million)
  • TABLE 31 MEA Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 32 MEA Male Infertility market, by treatment, 2015 - 2027 (USD Million)
  • TABLE 33 South Africa Male Infertility market, by test, 2015 - 2027 (USD Million)
  • TABLE 34 South Africa Male Infertility market, by treatment, 2015 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market formulation & validation
  • FIG. 8 Male infertility market outlook, 2019 (USD Million)
  • FIG. 9 Market trends & outlook
  • FIG. 10 Male infertility market segmentation
  • FIG. 11 Penetration & growth prospect mapping
  • FIG. 12 Market driver relevance analysis (Current & future impact)
  • FIG. 13 Market restraint relevance analysis (Current & future impact)
  • FIG. 14 Porter's five forces analysis
  • FIG. 15 PESTEL analysis
  • FIG. 16 Male infertility test market share analysis, 2019 & 2027
  • FIG. 17 Male infertility test market: Segment dashboard
  • FIG. 18 DNA fragmentation technique market, 2015 - 2027 (USD Million)
  • FIG. 19 Oxidative stress analysis market, 2015 - 2027 (USD Million)
  • FIG. 20 Microscopic examination market, 2015 - 2027 (USD Million)
  • FIG. 21 Sperm agglutination market, 2015 - 2027 (USD Million)
  • FIG. 22 Computer assisted semen analysis market, 2015 - 2027 (USD Million)
  • FIG. 23 Sperm penetration assay market, 2015 - 2027 (USD Million)
  • FIG. 24 Others market, 2015 - 2027 (USD Million)
  • FIG. 25 Male infertility treatment market share analysis, 2019 & 2027
  • FIG. 26 Male infertility treatment market: Segment dashboard
  • FIG. 27 ART & varicocele surgery market, 2015 - 2027 (USD Million)
  • FIG. 28 Medication market, 2015 - 2027 (USD Million)
  • FIG. 29 Male infertility regional market share analysis, 2019 & 2027
  • FIG. 30 Male infertility regional market: Segment dashboard
  • FIG. 31 Regional market place: Key takeaways
  • FIG. 32 SWOT analysis: North America
  • FIG. 33 SWOT analysis: Europe
  • FIG. 34 SWOT analysis: Asia Pacific
  • FIG. 35 SWOT analysis: Latin America
  • FIG. 36 SWOT analysis: MEA
  • FIG. 37 North America male infertility market, 2015 - 2027 (USD Million)
  • FIG. 38 U.S. male infertility market, 2015 - 2027 (USD Million)
  • FIG. 39 Canada male infertility market, 2015 - 2027 (USD Million)
  • FIG. 40 Europe male infertility market, 2015 - 2027 (USD Million)
  • FIG. 41 U.K. male infertility market, 2015 - 2027 (USD Million)
  • FIG. 42 Germany male infertility market, 2015 - 2027 (USD Million)
  • FIG. 43 Asia Pacific male infertility market, 2015 - 2027 (USD Million)
  • FIG. 44 Japan male infertility market, 2015 - 2027 (USD Million)
  • FIG. 45 China male infertility market, 2015 - 2027 (USD Million)
  • FIG. 46 Latin America male infertility market, 2015 - 2027 (USD Million)
  • FIG. 47 Brazil male infertility market, 2015 - 2027 (USD Million)
  • FIG. 48 Mexico male infertility market, 2015 - 2027 (USD Million)
  • FIG. 49 MEA male infertility market, 2015 - 2027 (USD Million)
  • FIG. 50 South Africa male infertility market, 2015 - 2027 (USD Million)
  • FIG. 51 Strategy framework
  • FIG. 52 Male infertility competitive landscape: Market position analysis (based on products, regional presence, and recent updates (2019))